FITZGERALD EDWARD M 4

What Happened

• Edward M. Fitzgerald, a director of Parabilis Medicines, converted a set of preferred securities into a total of 31,797 shares of common stock. The Form 4 lists six conversion transactions (transaction code C) dated June 11, 2026; no cash price is shown because these were conversions of existing preferred shares rather than open‑market purchases or sales.
• The conversions were automatic and occurred in connection with the company's initial public offering: per the filing footnotes, Series B, Series C and Series F preferred shares converted into common stock immediately prior to the closing of the IPO. The filing does not show a cash value paid for the shares (N/A).

Key Details

• Transaction dates: conversions reported as June 11, 2026; IPO closing and automatic conversions occurred immediately prior to June 9, 2026 (per footnotes).
• Shares acquired via conversion: 31,797 common shares in total (sum of six conversion entries: 5,539; 3,878; 5,271; 5,332; 3,666; 8,111).
• Prices/consideration: N/A — these were conversions of preferred into common (not purchases or sales).
• Conversion ratios (from filing footnotes): Series B converted at 1 → 1.0389; Series C at 1 → 1.0578; Series F at 1 → 0.6498.
• Shares owned after transaction: not specified in the excerpt provided here — see the full Form 4 for post‑transaction beneficial ownership.
• Filing: Form 4 filed June 15, 2026 reporting the transactions linked to the IPO period; consult the full filing for any timeliness flags or additional notes.

Context

• These were conversions of preferred stock into common stock tied to the IPO, not purchases or sales. Conversions typically do not involve cash changing hands and are a structural change in security type ahead of public trading.
• Such conversions increase the insider's common‑share count (and potential liquidity) but are not necessarily a signal of buying or selling intent. For complete context (post‑transaction holdings, any subsequent sales, or restrictions), review the full Form 4 and related disclosures.